One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial

EuroIntervention 2018;14:877-883 published online July 2018. DOI: 10.4244/EIJ-D-18-00460

Patrick Serruys
Patrick W. Serruys1*, MD, PhD; Rodrigo Modolo2, MD; Michael Reardon3, MD, PhD; Yosuke Miyazaki4, MD, PhD; Stephan Windecker5, MD, PhD; Jeffrey Popma6, MD, PhD; Yanping Chang7, MS; Neal S. Kleiman3, MD; Scott Lilly8, MD, PhD; Hafid Amrane9, MD, PhD; Piet W. Boonstra9, MD, PhD; Arie Pieter Kappetein7, MD, PhD; Yoshinobu Onuma4,10, MD, PhD; Lars Søndergaard11, MD, PhD; Nicolas van Mieghem4, MD, PhD
1. International Centre for Circulatory Health, NHLI, Imperial College London, London, United Kingdom; 2. Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 3. Houston Methodist DeBakey Heart and Vascul

Aims: The indication for transcatheter aortic valve implantation (TAVI) has evolved from inoperable patients to patients at increased surgical risk. In low-risk patients, surgical aortic

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

aortic stenosisno specific risktavi
Interventions for valvular diseaseTAVI
Read next article
Bioprosthetic Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction (BASILICA) during transcatheter aortic valve-in-valve implantation with bioprosthetic valve fracturing via the transcaval access

Latest news